Skip to main content
. Author manuscript; available in PMC: 2010 Jul 22.
Published in final edited form as: J Allergy Clin Immunol. 2007 Nov;120(5):1178–1185. doi: 10.1016/j.jaci.2007.10.001

FIG 1.

FIG 1

Heterozygous mutations may lead to reduced ligand binding. B cells (EBV cell lines) of subjects with TACI mutations indicated were tested to determine the binding of APRIL in comparison with the controls indicated. The mean fluorescence intensity (MFI, x-axis) for B cells (cell counts, y-axis) is shown. Isotype controls are marked in closed areas, surface APRIL fluorescence in open areas. NL, Normal.

HHS Vulnerability Disclosure